Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 3/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.41 |
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.39 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.39 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612466 | 1.00 | PBK (0.47) | PBKCHRNB2CHRNA4BTKCHRNB4 | |
| SCHEMBL3611678 | 1.00 | PBK (0.47) | PBKCHRNB2CHRNA4BTKCHRNB4 | |
| SCHEMBL3606194 | 0.93 | PBK (0.39) | PBKCHRNB2CHRNA4BTKCHRNB4 | |
| SCHEMBL3597756 | 0.93 | PBK (0.39) | PBKCHRNB2CHRNA4BTKCHRNB4 | |
| SCHEMBL3597760 | 0.93 | PBK (0.39) | PBKCHRNB2CHRNA4BTKCHRNB4 | |
| SCHEMBL3593688 | 0.90 | PBK (0.41) | PBKBTK | |
| SCHEMBL3593692 | 0.90 | PBK (0.41) | PBKBTK | |
| SCHEMBL3605993 | 0.79 | MAPK1 (0.46) | PBKCHRNB2CHRNA4CHRNB4CHEK1 | |
| SCHEMBL3614136 | 0.79 | MAPK1 (0.46) | PBKCHRNB2CHRNA4CHRNB4CHEK1 | |
| SCHEMBL3605989 | 0.79 | MAPK1 (0.46) | PBKCHRNB2CHRNA4CHRNB4CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | PBK 2463/4885CHRNB2 743/4885CHRNA4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.